{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T07:55:51Z","timestamp":1791964551253,"version":"4.3.4"},"reference-count":134,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","gastro.theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.gtc.2016.04.007","type":"journal-article","created":{"date-parts":[[2016,8,18]],"date-time":"2016-08-18T09:00:32Z","timestamp":1471510832000},"page":"487-507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Neuroendocrine Tumors"],"prefix":"10.1016","volume":"45","author":[{"given":"Ron","family":"Basuroy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Srirajaskanthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Ramage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.gtc.2016.04.007_bib1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2011-300831","article-title":"Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)","volume":"61","author":"Ramage","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2016.04.007_bib2","series-title":"WHO classification of tumours of the digestive system","author":"Bosman","year":"2010"},{"issue":"6021","key":"10.1016\/j.gtc.2016.04.007_bib3","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1200609","article-title":"DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors","volume":"331","author":"Jiao","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.gtc.2016.04.007_bib4","series-title":"International classification of diseases for oncology","author":"World Health Organization","year":"2000"},{"key":"10.1016\/j.gtc.2016.04.007_bib5","first-page":"292","article-title":"Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: a SEER analysis","volume":"3","author":"Tsikitis","year":"2012","journal-title":"J\u00a0Cancer"},{"issue":"4","key":"10.1016\/j.gtc.2016.04.007_bib6","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.11105","article-title":"A\u00a05-decade analysis of 13,715 carcinoid tumors","volume":"97","author":"Modlin","year":"2003","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.gtc.2016.04.007_bib7","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1677\/ERC-10-0152","article-title":"Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters","volume":"17","author":"Niederle","year":"2010","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"10.1016\/j.gtc.2016.04.007_bib8","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s00535-009-0194-8","article-title":"Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan","volume":"45","author":"Ito","year":"2010","journal-title":"J\u00a0Gastroenterol"},{"issue":"12","key":"10.1016\/j.gtc.2016.04.007_bib9","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1038\/ajg.2010.341","article-title":"Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971","volume":"105","author":"Ellis","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.gtc.2016.04.007_bib10","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1002\/cncr.23883","article-title":"Neuroendocrine tumor epidemiology: contrasting Norway and North America","volume":"113","author":"Hauso","year":"2008","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.gtc.2016.04.007_bib11","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1002\/1097-0142(20011015)92:8<2204::AID-CNCR1564>3.0.CO;2-R","article-title":"Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden","volume":"92","author":"Hemminki","year":"2001","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.gtc.2016.04.007_bib12","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1023\/A:1012272314550","article-title":"Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients","volume":"12","author":"Quaedvlieg","year":"2001","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.gtc.2016.04.007_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/SLA.0b013e31818e4641","article-title":"Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years","volume":"249","author":"Bilimoria","year":"2009","journal-title":"Ann Surg"},{"issue":"8","key":"10.1016\/j.gtc.2016.04.007_bib14","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1097\/DCR.0b013e318291f512","article-title":"Examining rectal carcinoids in the era of screening colonoscopy: a surveillance, epidemiology, and end results analysis","volume":"56","author":"Taghavi","year":"2013","journal-title":"Dis Colon Rectum"},{"issue":"7","key":"10.1016\/j.gtc.2016.04.007_bib15","first-page":"1051","article-title":"Site distribution of gastrointestinal carcinoids differs between races","volume":"55","author":"Konishi","year":"2006","journal-title":"Gut"},{"issue":"Suppl 10","key":"10.1016\/j.gtc.2016.04.007_bib16","first-page":"S32","article-title":"Changes in colorectal cancer during a 20-year period: an extended report from the multi-institutional registry of large bowel cancer","volume":"46","author":"Kotake","year":"2003","journal-title":"Dis Colon Rectum"},{"issue":"4","key":"10.1016\/j.gtc.2016.04.007_bib17","first-page":"322","article-title":"Carcinoid tumours. Frequency in a defined population during a 12-year period","volume":"84","author":"Berge","year":"1976","journal-title":"Acta Pathol Microbiol Scand A"},{"issue":"18","key":"10.1016\/j.gtc.2016.04.007_bib18","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.gtc.2016.04.007_bib19","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/archsurg.1994.01420330079015","article-title":"Neuroendocrine gut neoplasms. Important lessons from uncommon tumors","volume":"129","author":"Debas","year":"1994","journal-title":"Arch Surg"},{"issue":"4","key":"10.1016\/j.gtc.2016.04.007_bib20","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/ajco.12046","article-title":"Multiple endocrine neoplasia type 1 (MEN1)","volume":"9","author":"Carroll","year":"2013","journal-title":"Asia Pac J Clin Oncol"},{"issue":"3","key":"10.1016\/j.gtc.2016.04.007_bib21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/gcc.10081","article-title":"Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas, and abdominal paragangliomas","volume":"34","author":"Kytola","year":"2002","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"10.1016\/j.gtc.2016.04.007_bib22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000343232","article-title":"Profiling of ileal carcinoids","volume":"97","author":"Nilsson","year":"2013","journal-title":"Neuroendocrinology"},{"issue":"6","key":"10.1016\/j.gtc.2016.04.007_bib23","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1172\/JCI67963","article-title":"The genomic landscape of small intestine neuroendocrine tumors","volume":"123","author":"Banck","year":"2013","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.gtc.2016.04.007_bib24","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1053\/j.gastro.2013.10.020","article-title":"Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors","volume":"146","author":"Marinoni","year":"2014","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.gtc.2016.04.007_bib25","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2005.03.038","article-title":"Current status of gastrointestinal carcinoids","volume":"128","author":"Modlin","year":"2005","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.gtc.2016.04.007_bib26","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/bjc.2012.560","article-title":"Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours","volume":"108","author":"Yadegarfar","year":"2013","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.gtc.2016.04.007_bib27","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.bpg.2012.12.002","article-title":"Neuroendocrine tumours of the small intestine","volume":"26","author":"Strosberg","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"10","key":"10.1016\/j.gtc.2016.04.007_bib28","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1200\/JCO.1987.5.10.1502","article-title":"Karnofsky Memorial Lecture. An odyssey in the land of small tumors","volume":"5","author":"Moertel","year":"1987","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.gtc.2016.04.007_bib29","first-page":"720","article-title":"Mesenteric angiopathy, intestinal gangrene, and midgut carcinoids","volume":"90","author":"Eckhauser","year":"1981","journal-title":"Surgery"},{"issue":"11","key":"10.1016\/j.gtc.2016.04.007_bib30","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJM199903183401107","article-title":"Carcinoid tumors","volume":"340","author":"Kulke","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.gtc.2016.04.007_bib31","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1161\/01.CIR.77.2.264","article-title":"Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities","volume":"77","author":"Lundin","year":"1988","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.gtc.2016.04.007_bib32","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1161\/01.CIR.92.4.790","article-title":"Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography","volume":"92","author":"Robiolio","year":"1995","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.gtc.2016.04.007_bib33","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s00384-010-0949-y","article-title":"Clinicopathological characteristics of rectal carcinoids","volume":"25","author":"Yoon","year":"2010","journal-title":"Int J Colorectal Dis"},{"issue":"3","key":"10.1016\/j.gtc.2016.04.007_bib34","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000355612","article-title":"Clinical and prognostic features of rectal neuroendocrine tumors","volume":"98","author":"Weinstock","year":"2013","journal-title":"Neuroendocrinology"},{"issue":"1","key":"10.1016\/j.gtc.2016.04.007_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ecl.2010.12.005","article-title":"The epidemiology of gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Lawrence","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"10.1016\/j.gtc.2016.04.007_bib36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11894-010-0158-4","article-title":"A\u00a0clinical perspective on gastric neuroendocrine neoplasia","volume":"13","author":"Lawrence","year":"2011","journal-title":"Curr Gastroenterol Rep"},{"issue":"10","key":"10.1016\/j.gtc.2016.04.007_bib37","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/apt.12698","article-title":"Review article: the investigation and management of gastric neuroendocrine tumours","volume":"39","author":"Basuroy","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.gtc.2016.04.007_bib38","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00423-011-0794-7","article-title":"The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant","volume":"396","author":"Modlin","year":"2011","journal-title":"Langenbecks Arch Surg"},{"key":"10.1016\/j.gtc.2016.04.007_bib39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1756-8722-4-29","article-title":"Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors","volume":"4","author":"Kulke","year":"2011","journal-title":"J\u00a0Hematol Oncol"},{"issue":"1","key":"10.1016\/j.gtc.2016.04.007_bib40","doi-asserted-by":"crossref","first-page":"28","DOI":"10.5306\/wjco.v2.i1.28","article-title":"Imaging of gastroenteropancreatic neuroendocrine tumors","volume":"2","author":"Tan","year":"2011","journal-title":"World J Clin Oncol"},{"issue":"2","key":"10.1016\/j.gtc.2016.04.007_bib41","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.beem.2004.11.013","article-title":"Imaging and localization of islet-cell tumours of the pancreas on CT and MRI","volume":"19","author":"Noone","year":"2005","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.gtc.2016.04.007_bib42","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1148\/radiology.206.1.9423664","article-title":"Carcinoid metastases to the liver: role of triple-phase helical CT","volume":"206","author":"Paulson","year":"1998","journal-title":"Radiology"},{"issue":"886","key":"10.1016\/j.gtc.2016.04.007_bib43","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1259\/bjr.74.886.740968","article-title":"MRI of pancreatic neuroendocrine tumours","volume":"74","author":"Owen","year":"2001","journal-title":"Br J Radiol"},{"issue":"2","key":"10.1016\/j.gtc.2016.04.007_bib44","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/(SICI)1522-2586(200002)11:2<141::AID-JMRI10>3.0.CO;2-U","article-title":"Neuroendocrine tumors of the pancreas: spectrum of appearances on MRI","volume":"11","author":"Semelka","year":"2000","journal-title":"J\u00a0Magn Reson Imaging"},{"issue":"3","key":"10.1016\/j.gtc.2016.04.007_bib45","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/jmri.1182","article-title":"MRI of carcinoid tumors: spectrum of appearances in the gastrointestinal tract and liver","volume":"14","author":"Bader","year":"2001","journal-title":"J\u00a0Magn Reson Imaging"},{"issue":"1","key":"10.1016\/j.gtc.2016.04.007_bib46","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2214\/ajr.180.1.1800121","article-title":"MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques","volume":"180","author":"Dromain","year":"2003","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.gtc.2016.04.007_bib47","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2214\/AJR.07.2550","article-title":"Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization","volume":"190","author":"Liapi","year":"2008","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"10.1016\/j.gtc.2016.04.007_bib48","first-page":"528","article-title":"Successful preoperative localization of a small pancreatic insulinoma by diffusion-weighted MRI","volume":"10","author":"Anaye","year":"2009","journal-title":"JOP"},{"issue":"4","key":"10.1016\/j.gtc.2016.04.007_bib49","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/jmri.21508","article-title":"Quantitative analysis of diffusion-weighted magnetic resonance imaging of the pancreas: usefulness in characterizing solid pancreatic masses","volume":"28","author":"Lee","year":"2008","journal-title":"J\u00a0Magn Reson Imaging"},{"issue":"1","key":"10.1016\/j.gtc.2016.04.007_bib50","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1385\/MO:20:1:59","article-title":"Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors","volume":"20","author":"Fjallskog","year":"2003","journal-title":"Med Oncol"},{"issue":"3","key":"10.1016\/j.gtc.2016.04.007_bib51","first-page":"187","article-title":"Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors","volume":"5","author":"Kaemmerer","year":"2012","journal-title":"Int J Clin Exp Pathol"},{"issue":"Suppl 1","key":"10.1016\/j.gtc.2016.04.007_bib52","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1530\/ERC-10-0282","article-title":"Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours","volume":"18","author":"Teunissen","year":"2011","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"10.1016\/j.gtc.2016.04.007_bib53","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1007\/s00259-013-2482-z","article-title":"Somatostatin receptor PET\/CT in neuroendocrine tumours: update on systematic review and meta-analysis","volume":"40","author":"Geijer","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.gtc.2016.04.007_bib54","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2967\/jnumed.109.069765","article-title":"Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET","volume":"51","author":"Binderup","year":"2010","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.gtc.2016.04.007_bib55","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2217\/ije.15.9","article-title":"Personalized medicine for gastroenteropancreatic neuroendocrine tumors: a distant dream?","volume":"2","author":"Basuroy","year":"2015","journal-title":"Int J Endocr Oncol"},{"issue":"3","key":"10.1016\/j.gtc.2016.04.007_bib56","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1200\/JCO.2012.44.2905","article-title":"Circulating tumor cells as prognostic markers in neuroendocrine tumors","volume":"31","author":"Khan","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.gtc.2016.04.007_bib57","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.surg.2015.06.056","article-title":"Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies","volume":"159","author":"Modlin","year":"2016","journal-title":"Surgery"},{"issue":"5","key":"10.1016\/j.gtc.2016.04.007_bib58","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00259-015-3250-z","article-title":"Measurement of circulating transcripts and\u00a0gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors","volume":"43","author":"Bodei","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.gtc.2016.04.007_bib59","doi-asserted-by":"crossref","first-page":"E1437","DOI":"10.1210\/jc.2015-2792","article-title":"Circulating transcript analysis (NETest) in GEP-NETs treated with somatostatin analogs defines therapy","volume":"100","author":"Cwikla","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.gtc.2016.04.007_bib60","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ecl.2010.12.001","article-title":"The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Lawrence","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"7","key":"10.1016\/j.gtc.2016.04.007_bib61","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.cgh.2008.02.052","article-title":"Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors","volume":"6","author":"Arnold","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.gtc.2016.04.007_bib62","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1677\/ERC-08-0301","article-title":"Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma","volume":"16","author":"Durante","year":"2009","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"10.1016\/j.gtc.2016.04.007_bib63","doi-asserted-by":"crossref","first-page":"e0124884","DOI":"10.1371\/journal.pone.0124884","article-title":"Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis","volume":"10","author":"Yang","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.gtc.2016.04.007_bib64","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.humpath.2004.09.018","article-title":"Siegfried Oberndorfer: origins and perspectives of carcinoid tumors","volume":"35","author":"Modlin","year":"2004","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.gtc.2016.04.007_bib65","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.surg.2015.09.012","article-title":"Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: morphology matters","volume":"159","author":"Crippa","year":"2016","journal-title":"Surgery"},{"issue":"4","key":"10.1016\/j.gtc.2016.04.007_bib66","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000324770","article-title":"Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: a systematic review","volume":"93","author":"Capurso","year":"2011","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.gtc.2016.04.007_bib67","first-page":"420795","article-title":"ENETS TNM staging predicts prognosis in small bowel neuroendocrine tumours","volume":"2013","author":"Srirajaskanthan","year":"2013","journal-title":"ISRN Oncol"},{"issue":"3","key":"10.1016\/j.gtc.2016.04.007_bib68","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1677\/ERC-09-0042","article-title":"Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study","volume":"16","author":"Ahmed","year":"2009","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.gtc.2016.04.007_bib69","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.hoc.2015.09.001","article-title":"Surgical treatment of small bowel neuroendocrine tumors","volume":"30","author":"Farley","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"10.1016\/j.gtc.2016.04.007_bib70","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/bjs.6468","article-title":"Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease","volume":"96","author":"Frilling","year":"2009","journal-title":"Br J Surg"},{"key":"10.1016\/j.gtc.2016.04.007_bib71","doi-asserted-by":"crossref","first-page":"819193","DOI":"10.1155\/2012\/819193","article-title":"A\u00a0multimodal approach to the management of neuroendocrine tumour liver metastases","volume":"2012","author":"Basuroy","year":"2012","journal-title":"Int J Hepatol"},{"issue":"4","key":"10.1016\/j.gtc.2016.04.007_bib72","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S1072-7515(00)00222-2","article-title":"Hepatic neuroendocrine metastases: does intervention alter outcomes?","volume":"190","author":"Chamberlain","year":"2000","journal-title":"J\u00a0Am Coll Surg"},{"issue":"1","key":"10.1016\/j.gtc.2016.04.007_bib73","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0002-9610(99)80107-X","article-title":"Hepatic resection for metastatic neuroendocrine carcinomas","volume":"169","author":"Que","year":"1995","journal-title":"Am J Surg"},{"issue":"2","key":"10.1016\/j.gtc.2016.04.007_bib74","article-title":"Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases","author":"Gurusamy","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.gtc.2016.04.007_bib75","article-title":"Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours","author":"Gurusamy","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.gtc.2016.04.007_bib76","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S1470-2045(13)70362-0","article-title":"Recommendations for management of patients with neuroendocrine liver metastases","volume":"15","author":"Frilling","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.gtc.2016.04.007_bib77","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00261-004-0258-4","article-title":"Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience","volume":"30","author":"Gillams","year":"2005","journal-title":"Abdom Imaging"},{"issue":"8","key":"10.1016\/j.gtc.2016.04.007_bib78","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/cncr.21389","article-title":"Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival","volume":"104","author":"Gupta","year":"2005","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.gtc.2016.04.007_bib79","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.beem.2007.01.005","article-title":"Cytotoxic treatment including embolization\/chemoembolization for neuroendocrine tumours","volume":"21","author":"Toumpanakis","year":"2007","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.gtc.2016.04.007_bib80","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1002\/1097-0142(19930415)71:8<2624::AID-CNCR2820710830>3.0.CO;2-B","article-title":"Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients","volume":"71","author":"Ruszniewski","year":"1993","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.gtc.2016.04.007_bib81","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1148\/radiology.189.2.7692465","article-title":"Transcatheter chemoembolization of progressive carcinoid liver metastasis","volume":"189","author":"Therasse","year":"1993","journal-title":"Radiology"},{"issue":"Suppl 3","key":"10.1016\/j.gtc.2016.04.007_bib82","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000201208","article-title":"Hepatic arterial chemoembolization for metastatic neuroendocrine tumors","volume":"55","author":"Clouse","year":"1994","journal-title":"Digestion"},{"issue":"5","key":"10.1016\/j.gtc.2016.04.007_bib83","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0002-9610(99)80210-4","article-title":"Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization","volume":"169","author":"Diaco","year":"1995","journal-title":"Am J Surg"},{"issue":"1","key":"10.1016\/j.gtc.2016.04.007_bib84","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s00330-002-1558-0","article-title":"Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors","volume":"13","author":"Roche","year":"2003","journal-title":"Eur Radiol"},{"issue":"7","key":"10.1016\/j.gtc.2016.04.007_bib85","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3109\/07357909909032856","article-title":"Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma","volume":"17","author":"Kim","year":"1999","journal-title":"Cancer Invest"},{"issue":"5","key":"10.1016\/j.gtc.2016.04.007_bib86","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0002-9610(98)00042-7","article-title":"Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors","volume":"175","author":"Drougas","year":"1998","journal-title":"Am J Surg"},{"issue":"1","key":"10.1016\/j.gtc.2016.04.007_bib87","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/sj.bjc.6603526","article-title":"Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours","volume":"96","author":"Marrache","year":"2007","journal-title":"Br J Cancer"},{"issue":"38","key":"10.1016\/j.gtc.2016.04.007_bib88","first-page":"333","article-title":"Selective internal radiation therapy (SIRT) with 90Yttrium microspheres for extensive colorectal liver metastases","volume":"48","author":"Stubbs","year":"2001","journal-title":"Hepatogastroenterology"},{"issue":"3","key":"10.1016\/j.gtc.2016.04.007_bib89","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/COC.0b013e31815e4557","article-title":"Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients","volume":"31","author":"Kennedy","year":"2008","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"10.1016\/j.gtc.2016.04.007_bib90","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/cncr.23685","article-title":"Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases","volume":"113","author":"King","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.gtc.2016.04.007_bib91","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jvir.2007.09.006","article-title":"Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization","volume":"19","author":"Murthy","year":"2008","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.gtc.2016.04.007_bib92","first-page":"1","article-title":"Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases","author":"Barbier","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.gtc.2016.04.007_bib93","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1056\/NEJM199601253340408","article-title":"Octreotide","volume":"334","author":"Lamberts","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.gtc.2016.04.007_bib94","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bpg.2005.02.012","article-title":"Endocrine tumours of the gastrointestinal tract. Biotherapy for metastatic endocrine tumours","volume":"19","author":"Shah","year":"2005","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"4","key":"10.1016\/j.gtc.2016.04.007_bib95","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0","article-title":"Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance","volume":"88","author":"O'toole","year":"2000","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.gtc.2016.04.007_bib96","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdh216","article-title":"Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system","volume":"15","author":"Oberg","year":"2004","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.gtc.2016.04.007_bib97","first-page":"145","article-title":"Neuroendocrine tumors. Biotherapy","volume":"21","author":"Plockinger","year":"2007","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"28","key":"10.1016\/j.gtc.2016.04.007_bib98","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.gtc.2016.04.007_bib99","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gtc.2016.04.007_bib100","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.2147\/DDDT.S84177","article-title":"Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues","volume":"9","author":"Wolin","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"21","key":"10.1016\/j.gtc.2016.04.007_bib101","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJM198011203032101","article-title":"Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma","volume":"303","author":"Moertel","year":"1980","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.gtc.2016.04.007_bib102","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ejca.2013.12.011","article-title":"Capecitabine and streptozocin \u00b1 cisplatin in advanced gastroenteropancreatic neuroendocrine tumours","volume":"50","author":"Meyer","year":"2014","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.gtc.2016.04.007_bib103","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-06-2053","article-title":"Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors","volume":"13","author":"Ekeblad","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"4 Suppl 1","key":"10.1016\/j.gtc.2016.04.007_bib104","first-page":"S10","article-title":"Advances in the treatment of pancreatic neuroendocrine tumors (pNETs)","volume":"6","author":"Strosberg","year":"2013","journal-title":"Gastrointest Cancer Res"},{"issue":"5","key":"10.1016\/j.gtc.2016.04.007_bib105","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.20466","article-title":"A\u00a0phase II trial of gemcitabine for metastatic neuroendocrine tumors","volume":"101","author":"Kulke","year":"2004","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.gtc.2016.04.007_bib106","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJM199202203260804","article-title":"Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma","volume":"326","author":"Moertel","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.gtc.2016.04.007_bib107","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/1097-0142(19900501)65:9<1883::AID-CNCR2820650902>3.0.CO;2-3","article-title":"Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors","volume":"65","author":"Eriksson","year":"1990","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.gtc.2016.04.007_bib108","first-page":"327","article-title":"Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome","volume":"2","author":"Moertel","year":"1979","journal-title":"Cancer Clin Trials"},{"issue":"22","key":"10.1016\/j.gtc.2016.04.007_bib109","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1200\/JCO.2005.03.616","article-title":"Phase II\/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281","volume":"23","author":"Sun","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.gtc.2016.04.007_bib110","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s10620-006-8001-3","article-title":"A\u00a0phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors","volume":"51","author":"Kulke","year":"2006","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.gtc.2016.04.007_bib111","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00000421-199802000-00008","article-title":"Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma","volume":"21","author":"Rivera","year":"1998","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"10.1016\/j.gtc.2016.04.007_bib112","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1200\/JCO.2005.03.6046","article-title":"Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors","volume":"24","author":"Kulke","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.gtc.2016.04.007_bib113","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I","article-title":"Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms","volume":"68","author":"Moertel","year":"1991","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.gtc.2016.04.007_bib114","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.bjc.6690325","article-title":"Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin","volume":"81","author":"Mitry","year":"1999","journal-title":"Br J Cancer"},{"issue":"15S","key":"10.1016\/j.gtc.2016.04.007_bib115","doi-asserted-by":"crossref","first-page":"15550","DOI":"10.1200\/jco.2008.26.15_suppl.15550","article-title":"A\u00a0phase II study of irinotecan and cisplatin for metastatic or unresectable high grade neuroendocrine carcinoma","volume":"26","author":"Mani","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.gtc.2016.04.007_bib116","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.gtc.2016.04.007_bib117","doi-asserted-by":"crossref","unstructured":"Strosberg JR, Wolin EM, Chasen B, et al. NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate. J Clin Oncol 34, 2016 (suppl 4S; abstr 194).","DOI":"10.1200\/jco.2016.34.4_suppl.194"},{"issue":"12","key":"10.1016\/j.gtc.2016.04.007_bib118","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1200\/JCO.2005.08.066","article-title":"Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors","volume":"23","author":"Kwekkeboom","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.gtc.2016.04.007_bib119","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/02841860701441848","article-title":"Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours","volume":"46","author":"Van Essen","year":"2007","journal-title":"Acta Oncol"},{"issue":"10","key":"10.1016\/j.gtc.2016.04.007_bib120","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s00259-008-0778-1","article-title":"Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors","volume":"35","author":"Bodei","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.gtc.2016.04.007_bib121","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1097\/00006231-199409000-00008","article-title":"131I-MIBG as a first-line treatment in high-risk neuroblastoma patients","volume":"15","author":"Hoefnagel","year":"1994","journal-title":"Nucl Med Commun"},{"issue":"6","key":"10.1016\/j.gtc.2016.04.007_bib122","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.1996.14.6.1829","article-title":"Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors","volume":"14","author":"Taal","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.gtc.2016.04.007_bib123","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1053\/ejso.2001.1132","article-title":"(131)I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome","volume":"27","author":"Pathirana","year":"2001","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.gtc.2016.04.007_bib124","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1365-2265.2001.01309.x","article-title":"Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]","volume":"55","author":"Mukherjee","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"10.1016\/j.gtc.2016.04.007_bib125","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/00006231-199310000-00004","article-title":"Treatment of malignant phaeochromocytoma, paraganglioma and carcinoid tumours with 131I-metaiodobenzylguanidine","volume":"14","author":"Bomanji","year":"1993","journal-title":"Nucl Med Commun"},{"issue":"11","key":"10.1016\/j.gtc.2016.04.007_bib126","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/01.mnm.0000184941.06123.b9","article-title":"Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response","volume":"26","author":"Buscombe","year":"2005","journal-title":"Nucl Med Commun"},{"issue":"13","key":"10.1016\/j.gtc.2016.04.007_bib127","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1007\/s00259-015-3116-4","article-title":"Long-term outcomes of (131)Iodine mIBG therapy in metastatic gastrointestinal pancreatic neuroendocrine tumours: single administration predicts non-responders","volume":"42","author":"Mulholland","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.gtc.2016.04.007_bib128","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s002590050476","article-title":"Yttrium-90 DOTATOC: first clinical results","volume":"26","author":"Otte","year":"1999","journal-title":"Eur J Nucl Med"},{"issue":"5","key":"10.1016\/j.gtc.2016.04.007_bib129","first-page":"610","article-title":"Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC","volume":"43","author":"Waldherr","year":"2002","journal-title":"J\u00a0Nucl Med"},{"issue":"2","key":"10.1016\/j.gtc.2016.04.007_bib130","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/j.semnuclmed.2006.01.001","article-title":"Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors","volume":"36","author":"Valkema","year":"2006","journal-title":"Semin Nucl Med"},{"issue":"8","key":"10.1016\/j.gtc.2016.04.007_bib131","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/cr.2007.64","article-title":"Expanding mTOR signaling","volume":"17","author":"Yang","year":"2007","journal-title":"Cell Res"},{"issue":"Suppl 1","key":"10.1016\/j.gtc.2016.04.007_bib132","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10555-011-9290-3","article-title":"Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors","volume":"30","author":"Capdevila","year":"2011","journal-title":"Cancer Metastasis Rev"},{"issue":"10022","key":"10.1016\/j.gtc.2016.04.007_bib133","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.gtc.2016.04.007_bib134","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N\u00a0Engl J Med"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855316300395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855316300395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T05:06:03Z","timestamp":1657083963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889855316300395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":134,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0889855316300395"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2016.04.007","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuroendocrine Tumors","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gtc.2016.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2016 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}